EMD 2.44% 4.2¢ emyria limited

general talk, page-18

  1. 1,459 Posts.
    lightbulb Created with Sketch. 492
    Nothing us shareholders don't already know. It's just a brief report, no price targets. Only discussed CBD opportunity, didnt even mention MDMA.

    The gist was Emyria will likely be the first company to have their product on pharmacy shelves, and with a high quality product too. Could be quite a lucrative market.

    They did say they anticipate a CR soon.
 
watchlist Created with Sketch. Add EMD (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.